More concurrent chemotherapy cycles correlate with longer survival in locally advanced NSCLC

Receiving five to seven weekly chemotherapy cycles was associated with higher two-year survival, although early anemia independently predicted outcomes.

KEY POINTS

  • This retrospective single-center study included 90 patients with stage IIB–IIIC non-small cell lung cancer treated with definitive chemoradiotherapy between 2018 and 2022. All received weekly carboplatin AUC 2 plus paclitaxel 45 mg/m² with radiotherapy prescribed to 56–66 Gy, and 50 patients subsequently received durvalumab.
  • Patients were stratified according to completion of 1–4 chemotherapy cycles (n=22) or 5–7 cycles (n=68). Median follow-up was 33.5 months, and baseline stage, performance status, durvalumab use, and key radiotherapy dose parameters were broadly comparable between the two groups.
  • Patients receiving 5–7 cycles demonstrated significantly longer overall survival: median OS was not reached versus 17.4 months after 1–4 cycles (log-rank p=0.048). Estimated two-year OS was 70.6% versus 37.2%, an absolute difference of 33.4 percentage points.
  • When the number of chemotherapy cycles was analyzed continuously, each additional cycle was associated with improved survival (HR 0.75 per cycle, 95% CI 0.592–0.950; p=0.017). Two-year PFS estimates were also higher with 5–7 cycles (42.5% vs 16.6%).
  • Consolidation durvalumab showed a favorable but nonsignificant association with overall survival (HR 0.568, 95% CI 0.302–1.069; p=0.075). The highest estimated two-year OS, 74.4%, occurred among patients receiving both 5–7 chemotherapy cycles and durvalumab, compared with 22.9% among those receiving 1–4 cycles without durvalumab.
  • Early grade ≥2 anemia occurred in 50.0% of patients receiving 1–4 cycles versus 20.6% receiving 5–7 cycles (p=0.007). Anemia independently predicted worse OS (adjusted HR 2.29, 95% CI 1.15–4.54; p=0.018); after adjustment for anemia, the chemotherapy-cycle association was no longer statistically significant (HR 0.58; p=0.129).
  • Most clinical toxicities did not differ significantly by cycle number, but grade ≥2 lymphocytopenia was more frequent with 5–7 cycles (98.4% vs 85.0%; p=0.040). Only two patients developed clinically significant early grade ≥2 pneumonitis, limiting interpretation of pulmonary toxicity and survival associations.

CLINICAL TAKEAWAY

Completing planned weekly carboplatin/paclitaxel during definitive chemoradiotherapy was associated with better survival in this real-world NSCLC cohort, supporting efforts to maintain treatment intensity when safely feasible. However, the retrospective design, small cohort, and loss of the chemotherapy-cycle association after adjustment for anemia suggest that treatment completion may partly reflect patient fitness and tolerance rather than an independent benefit from additional cycles.

SOURCE

Strahlentherapie und Onkologie

Browse more research Suggest a correction